Topical application of PPARα (but not β/δ or γ) suppresses atopic dermatitis in NC/Nga mice

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 7, 2012, Pages 936-942

  Chiba, Takahito ^a   Takeuchi, S ^a   Esaki, H ^a   Yamamura, K ^a   Kurihara, Y ^a   Moroi, Y ^a   Furue, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Atopic dermatitis; NC Nga mice; Peroxisome proliferator activated receptor , , ; Topical application

Indexed keywords

BETAMETHASONE VALERATE; CIGLITAZONE; IMMUNOGLOBULIN E; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; CELL INFILTRATION; DERMIS; DISEASE MODEL; DOWN REGULATION; DRUG EFFICACY; EPIDERMIS; INFLAMMATORY CELL; MITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEROLOGY;

ANIMALS; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; EOSINOPHILS; EPIDERMIS; FEMALE; IMMUNOGLOBULIN E; MAST CELLS; MICE; PPAR ALPHA; PYRIMIDINES;

EID: 84862006467     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2012.02844.x     Document Type: Article

References (30)

1. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361:151-160. (Pubitemid 36092023)
2. Furue M. Atopic dermatitis - immunological abnormality and its background. J Dermatol Sci 1994;7:159-168. Review. (Pubitemid 24210887)
3. Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, Tazi-Ahnini R et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006;118:3-21. Review. (Pubitemid 43946484)
4. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Leung DY et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-1160.
5. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Van Voorhees AS et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol 2004;50:391-404.
6. Katayama I, Kohno Y, Akiyama K, Ikezawa Z, Kondo N, Kouro O et al. Japanese guideline for atopic dermatitis. Allergol Int 2011;60:205-220. Review.
7. Pels R, Sterry W, Lademann J. Clobetasol propionate-where, when, why? Drugs Today (Barc) 2008;44:547-557.
8. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-650.
9. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) g: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994;135:798-800. (Pubitemid 24241266)
10. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302:93-109. Review. (Pubitemid 26247079)
11. Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Feingold KR et al. Murine atopic dermatitis responds to peroxisome proliferator-activated receptors a and b/d (but not g) and liver X receptor activators. J Allergy Clin Immunol 2010;125:160-169.
12. Dahten A, Koch C, Ernst D, Schnöller C, Hartmann S, Worm M. Systemic PPAR γ ligation inhibits allergic immune response in the skin. J Invest Dermatol 2008;128:2211-2218.
13. Ueki S, Adachi T, Bourdeaux J, Oyamada H, Yamada Y, Chihara J et al. Expression of PPAR g in eosinophils and its functional role in survival and chemotaxis. Immunol Lett 2003;86:183-189. (Pubitemid 36324279)
14. Hirasawa H, Chiba T, Ueki S, Kamada Y, Ito W, Chihara J et al. The synthetic PPAR g agonist troglitazone inhibits eotaxinenhanced eosinophil adhesion to ICAM-1-coated plates. Int Arch Allergy Immunol 2008;146(Suppl 1):11-15.
15. Yamamoto M, Haruna T, Yasui K, Takahashi H, Iduhara M, Arimura A et al. A novel atopic dermatitis model induced by topical application with dermatophagoides farinae extract in NC/Nga mice. Allergol Int 2007;56:139-148. (Pubitemid 46984242)
16. Staumont-Sallé D, Abboud G, Brénuchon C, Kanda A, Roumier T, Dombrowicz D et al. Peroxisome proliferator-activated receptor a regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 2008;121:962-968.
17. Hashimoto Y, Arai I, Takano N, Tanaka M, Nakaike S. Induction of scratching behaviour and dermatitis in various strains of mice cohabiting with NC/Nga mice with chronic dermatitis. Br J Dermatol 2006;154:28-33. (Pubitemid 43381316)
18. Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol 2003;149:229-236. Review. (Pubitemid 37100245)
19. Gonzalez FJ. The role of peroxisome proliferator activated receptor a in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis. Adv Exp Med Biol 1997;422:109-125. Review. (Pubitemid 27479177)
20. Dubrac S, Schmuth M. PPARa in cutaneous inflammation. Dermatoendocrinol 2011;3:23-26.
21. Hanley K, Kömüves LG, Bass NM, He SS, Jiang Y, Feingold KR et al. Fetal epidermal differentiation and barrier development in vivo is accelerated by nuclear hormone receptor activators. J Invest Dermatol 1999;113:788-795.
22. Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Dombrowicz D et al. Peroxisome proliferator-activated receptors a and g down-regulate allergic inflammation and eosinophil activation. J Exp Med 2003;198:411-421. (Pubitemid 36976052)
23. Goetze S, Kim S, Xi XP, Graf K, Yang DC, Law RE et al. Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells. J Cardiovasc Pharmacol 2000;35:749-757. (Pubitemid 30253616)
24. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Koeffler HP et al. Ligand for peroxisome proliferator-activated receptor g (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-3352. (Pubitemid 28371075)
25. Ueki S, Adachi T, Bourdeaux J, Oyamada H, Yamada Y, Chihara J et al. Expression of PPARγ in eosinophils and its functional role in survival and chemotaxis. Immunol Lett 2003;86:183-189. (Pubitemid 36324279)
26. Törmä H, Berne B. Sodium lauryl sulphate alters the mRNA expression of lipid-metabolizing enzymes and PPAR signalling in normal human skin in vivo. Exp Dermatol 2009;18:1010-1015.
27. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Wahli W et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) a and PPARb mutant mice. J Cell Biol 2001;154:799-814. (Pubitemid 34292961)
28. Kippenberger S, Loitsch SM, Grundmann-Kollmann M, Simon S, Dang TA, Bernd A et al. Activators of peroxisome proliferatoractivated receptors protect human skin from ultraviolet-B-light-induced inflammation. J Invest Dermatol 2001;117:1430-1436. (Pubitemid 34032769)
29. Jiang YJ, Lu B, Kim P, Elias PM, Feingold KR. Regulation of ABCA1 expression in human keratinocytes and murine epidermis. Endocrinology 2006;147:4772-4780.
30. De Belilovsky C, Roo-Rodriguez E, Baudouin C, Menu F, Chadoutaud B, Msika P. Natural peroxisome proliferator-activated receptor-alpha agonist cream demonstrates similar therapeutic response to topical steroids in atopic dermatitis. J Dermatolog Treat 2011;22:359-365.